Page last updated: 2024-08-24
irinotecan and MI-63
irinotecan has been researched along with MI-63 in 1 studies
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, J; Ding, K; Kang, S; McEachern, D; Miller, R; Nikolovska-Coleska, Z; Qin, D; Qiu, S; Shangary, S; Wang, G; Wang, S; Yang, D; Yu, S | 1 |
Other Studies
1 other study(ies) available for irinotecan and MI-63
| Article | Year |
|---|---|
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Bone Neoplasms; Cell Line, Tumor; Drug Design; HCT116 Cells; Humans; Indoles; Mice; Morpholines; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-mdm2; Rats; Spiro Compounds; Structure-Activity Relationship; Tumor Suppressor Protein p53 | 2009 |